Search research articles
Contact Us
Filters
Showing results (321-330 of 331) with videos related to
Page
of 34
Sort By:
ACS Omega
|
October 5, 2021
Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
David M Cate, Joshua D Bishop, Helen V Hsieh, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
Dave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
BMJ Open
|
August 11, 2019
Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol
Harbinder K Sandhu, Charles Abraham, Sharisse Alleyne, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI
Sarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
Plos One
|
May 17, 2021
Characterization of oral swab samples for diagnosis of pulmonary tuberculosis
Rachel C Wood, Alfred Andama, Gleda Hermansky, et al.
The Lancet. Respiratory Medicine
|
November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
Nicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
David P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
ACS Omega
|
August 10, 2021
Screening Antibodies Raised against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays
Jason L Cantera, David M Cate, Allison Golden, et al.
Health Technology Assessment (Winchester, England)
|
May 15, 2026
Effects and costs of a group-based educational intervention to reduce opioid use in people with chronic pain: I-WOTCH RCT
Harbinder K Sandhu, Katie Booth, Sheeja Manchira Krishnan, et al.
The Journal of Experimental Medicine
|
June 14, 2017
Recurrent rhinovirus infections in a child with inherited MDA5 deficiency
Ian T Lamborn, Huie Jing, Yu Zhang, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 331) with videos related to
Sort By:
Page
of 34
ACS Omega
|
October 5, 2021
Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
David M Cate, Joshua D Bishop, Helen V Hsieh, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
Dave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
BMJ Open
|
August 11, 2019
Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol
Harbinder K Sandhu, Charles Abraham, Sharisse Alleyne, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI
Sarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
Plos One
|
May 17, 2021
Characterization of oral swab samples for diagnosis of pulmonary tuberculosis
Rachel C Wood, Alfred Andama, Gleda Hermansky, et al.
The Lancet. Respiratory Medicine
|
November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
Nicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
David P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
ACS Omega
|
August 10, 2021
Screening Antibodies Raised against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays
Jason L Cantera, David M Cate, Allison Golden, et al.
Health Technology Assessment (Winchester, England)
|
May 15, 2026
Effects and costs of a group-based educational intervention to reduce opioid use in people with chronic pain: I-WOTCH RCT
Harbinder K Sandhu, Katie Booth, Sheeja Manchira Krishnan, et al.
The Journal of Experimental Medicine
|
June 14, 2017
Recurrent rhinovirus infections in a child with inherited MDA5 deficiency
Ian T Lamborn, Huie Jing, Yu Zhang, et al.
Page
of 34